Risk factors for refractory patent ductus arteriosus to initial medical treatment in preterm infants

Year 2025, EARLY ONLINE, 1 - 8

Aybüke Yazıcı , Hayriye Gözde Kanmaz Kutman , Gülsüm Kadıoğlu Şimşek , Betül Siyah Bilgin , Fuat Emre Canpolat , Şerife Suna Oğuz

https://doi.org/10.18621/eurj.1610415

Abstract

Objectives: This study aims to identify risk factors and clinical markers for refractory patent ductus arteriosus to the initial medical treatment and determine appropriate treatment strategies. The goal is to define the newborns who will respond to treatment and to prevent patients from adverse effects of medical or surgical treatment of patent ductus arteriosus.

Methods: Preterm infants with hemodynamically significant patent ductus arteriosus and whose gestational age was under 30 weeks were retrospectively evaluated. Infants who responded to the initial medical treatment (paracetamol or ibuprofen) were compared to those non-responders. Neonatal characteristics and comorbidities were compared between the groups.

Results: Data from a total of 91 infants were analyzed. The mean gestational age was 27±1.9 weeks vs. 26±1.9 weeks (P=0.10), and birth weight was 1,056±290 vs. 974±318 g (P=0.61), respectively in responder and refractory groups. Success rates for patients treated with paracetamol (n=49) were 57.4%, while for those treated with ibuprofen (n=42), it was 42.6% (P=0.47). Echocardiographic findings such as ductal size 2.48±0.69 vs. 2.55±0.66 mm (P=0.75), and left atrium/aortic root ratio 1.73±0.4 vs. 1.64±0.25, (P=0.14) were also comparable. Incidence of severe intraventricular hemorrhage (22.7% vs 4.3%, P=0.009) and periventricular leukomalacia was significantly higher in the refractory group (53.1% vs. 22.2%, P=0.008).

Conclusions: Combining multiple risk factors into a clinical decision-making model or algorithm could enhance the predictive accuracy of treatment response. Moreover, ongoing monitoring and tailored treatment adjustments based on individual responses and side effects are crucial for effectively managing patent ductus arteriosus in preterm infants.

Keywords

Patent ductus arteriosus, preterm infants, treatment

Ethical Statement

The study was reviewed and approved by the ethics committee of University of Health Sciences, Ankara Bilkent City Hospital (Ethics approval decision no: E2-22-3045 and date: 23.12.2022). All participants signed informed written consent before being enrolled in the study. All procedures were performed according to the Declaration of Helsinki.

References

• 1. Clyman R. Ibuprofen and patent ductus arteriosus. N Eng J Med 2000;343(10):728-730. doi: 10.1056/NEJM200009073431009.
• 2. Gournay V. The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis. 2011;104(11):578-585. doi: 10.1016/j.acvd.2010.06.006.
• 3. Evans N. Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist? Semin Fetal Neonatal Med. 2015;20(4):272-277. doi: 10.1016/j.siny.2015.03.004.
• 4. Benitz WE, Bhombal S. The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants. Semin Fetal Neonatal Med. 2017;22(5):302-307. doi: 10.1016/j.siny.2017.07.004.
• 5. Jain A, Shah PS. Diagnosis, Evaluation, and Management of Patent Ductus Arteriosus in Preterm Neonates. JAMA Pediatr. 2015;169(9):863-782. doi: 10.1001/jamapediatrics.2015.0987.
• 6. Malviya MN, Ohlsson A, Shah SS. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2013;2013(3):CD003951. doi: 10.1002/14651858.CD003951.pub3.
• 7. Mitra S, Rønnestad A, Holmstrøm H. Management of patent ductus arteriosus in preterm infants-where do we stand? Congenit Heart Dis. 2013;8(6):500-512. doi: 10.1111/chd.12143.
• 8. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev 2020;1(1):CD010061. doi: 10.1002/14651858.CD010061.pub4.
• 9. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr. 2007;151(6):629-634. doi: 10.1016/j.jpeds.2007.05.007.
• 10. Hamrick SE, Hansman G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020-1030. doi: 10.1542/peds.2009-3506.
• 11. Pourarian S, Farahbakhsh N, Sharma D, Cheriki S, Bijanzadeh F. Prevalence and risk factors associated with the patency of ductus arteriosus in premature neonates: a prospective observational study from Iran. J Matern Fetal Neonatal Med. 2017;30(12):1460-1464. doi: 10.1080/14767058.2016.1219991.
• 12. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016;137(1):e20153730. doi: 10.1542/peds.2015-3730.
• 13. Kimani S, Surak A, Miller M, Bhattacharya S. Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates. Paediatr Child Health. 2020;26(4):177-183. doi: 10.1093/pch/pxaa057.
• 14. Yurttutan S, Bozkaya A, Hüdayioglu F, Oncel MY. The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants. J Matern Neonatal Med. 2018;32(21):1-4. doi: 10.1080/14767058.2018.1481043.
• 15. Erdeve O, Yurttutan S, Altuğ N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomized controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F279-283. doi: 10.1136/archdischild-2011-300532.
• 16. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Care Med. 2001;163(7):1723-1729. doi: 10.1164/ajrccm.163.7.2011060.
• 17. Özkan H, Erdeve Ö, Kutman HGK. Turkish Neonatal Society guideline on the management of respiratory distress syndrome and surfactant treatment. Turk Pediatri Ars. 2018;53(Suppl 1):S45-S54. doi: 10.5152/TurkPediatriArs.2018.01806.
• 18. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 g. J Pediatr. 1978;92(4):529-534. doi: 10.1016/s0022-3476(78)80282-0.
• 19. De Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res. 1992;49(1):1-6. doi: 10.1016/s0166-4328(05)80189-5.
• 20. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness. Curr Probl Pediatr 1987;17(4): 213-88. doi: 10.1016/0045-9380(87)90031-4.
• 21. Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128(10):e51-e68. doi: 10.1016/j.ophtha.2021.05.031.
• 22. Satar M, Arısoy AE, Çelik İH. Turkish Neonatal Society guideline on neonatal infections-diagnosis and treatment. Turk Pediatri Ars. 2018;53(Suppl 1):S88-S100. doi: 10.5152/TurkPediatriArs.2018.01809.
• 23. Kültürsay N, Bilgen H, Türkyılmaz C. Turkish Neonatal Society guideline on enteral feeding of the preterm infant. Turk Pediatri Ars. 2018;53(Suppl 1):S109-S118. doi: 10.5152/TurkPediatriArs.2018.01811.
• 24. Türkyılmaz C, Bilgen H, Kültürsay N. Turkish Neonatal Society guideline on parenteral nutrition in preterm infants. Turk Pediatri Ars. 2018;53(Suppl 1):S119-S127. doi: 10.5152/TurkPediatriArs.2018.01812.
• 25. Koch J. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113-1121. doi: 10.1542/peds.2005-1528.
• 26. Dani C, Mosca F, Cresi F, et al. Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention? Early Hum Dev.2019;135:16-22. doi: 10.1016/j.earlhumdev.2019.06.002.
• 27. Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr. 2003;143:203-207. doi: 10.1067/S0022-3476(03)00303-2.
• 28. Lee JA, Sohn JA, Oh S, Choi BM. Perinatal risk factors of symptomatic preterm patent ductus arteriosus and secondary ligation. Pediatr Neonatol. 2020;61:439-446. doi: 10.1016/j.pedneo.2020.03.016.
• 29. Rodrigo FGM, Henrıquez GG, Aloy JF, Perez AGA. Outcomes of very-low-birth- weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. Neonatology. 2014;106(3):229-234. doi: 10.1159/000363127.
• 30. Hamrick SEG, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020-1030. doi: 10.1542/peds.2009-3506.
• 31. Behbodi E, Villamor-Martínez E, Degraeuwe PL, Villamor E. Chorioamnionitis appears not to be a Risk Factor for Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis. Sci Rep. 2016;6:37967. doi: 10.1038/srep37967.
• 32. Harink T, Clur SAB, Lee R, Deutekom AW. Ductus arteriosus and failed medical therapy. J Neonatal Perinatal Med. 2020;13(1):39-45. doi: 10.3233/NPM-180152.
• 33. Liu T, Chen Z, Ma X, Shi L. Predictive tool for closure of ductus arteriosus with pharmacologic or surgical treatment in preterm infants. Pediatr Cardiol. 2022;43(2):373-381. doi: 10.1007/s00246-021-02731-w.
• 34. Olsson KW, Larsson A, Jonzon A, Sindelar R. Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks’ gestation. Pediatr Res. 2019;86(3):333-338. doi: 10.1038/s41390-018-0182-x.
• 35. Sallmon H, Timme N, Atasay B, et al. Current controversy on platelets and patent ductus arteriosus closure in preterm infants. Front Pediatr. 2021;9:612242. doi: 10.3389/fped.2021.612242.
• 36. Evans P, O’Reilly D, Flyer JN, Soll R, Mitra S. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2021;1(1):CD013133. doi: 10.1002/14651858.
• 37. Park J, Yoon SJ, Han J, Song I, Lim J, Shin JE, et al. Patent ductus arteriosus treatment trends and associated morbidities in neonates. Sci Rep. 2021; 11(1):10689. doi: 10.1038/s41598-021-89868-z.
• 38. Vaidya R, Knee A, Paris Y, Singh R. Predictors of successful patent ductus arteriosus closure with acetaminophen in preterm infants. J Perinatol. 2021;41(5):998-1006. doi: 10.1038/s41372-020-00803-y.